Remote-controlled eradication of astrogliosis in spinal cord injury via electromagnetically-induced dexamethasone release from “smart” nanowires  by Gao, Wen & Borgens, Richard Ben
Journal of Controlled Release 211 (2015) 22–27
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lRemote-controlled eradication of astrogliosis in spinal cord injury
via electromagnetically-induced dexamethasone release from
“smart” nanowiresWen Gao a, Richard Ben Borgens a,b,⁎
a Center for Paralysis Research, Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA
b Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA⁎ Corresponding author at: Center for Paralysis Resea
Lafayette, IN 47907, USA.
E-mail address: cpr@purdue.edu (R.B. Borgens).
http://dx.doi.org/10.1016/j.jconrel.2015.05.266
0168-3659/Published by Elsevier B.V.a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 February 2015
Received in revised form 7 May 2015
Accepted 11 May 2015
Available online 13 May 2015
Keywords:
Polypyrrole nanowires
Electromagnetic ﬁeld stimulation
Controlled drug release
Neuroinﬂammation
Spinal cord injury
Reactive astrogliosisWe describe a system to deliver drugs to selected tissues continuously, if required, for weeks. Drugs can be re-
leased remotely inside the small animals using pre-implanted, novel vertically aligned electromagnetically-
sensitive polypyrrole nanowires (PpyNWs). Approximately 1–2 mm2 dexamethasone (DEX) doped PpyNWs
was lifted on a single drop of sterile water by surface tension, and deposited onto a spinal cord lesion in glial
ﬁbrillary acidic protein-luc transgenic mice (GFAP-luc mice). Overexpression of GFAP is an indicator of
astrogliosis/neuroinﬂammation in CNS injury. The corticosteroid DEX, a powerful ameliorator of inﬂammation,
was released from the polymer by external application of an electromagnetic ﬁeld for 2 h/day for a week. The
GFAP signal, revealed by bioluminescent imaging in the living animal, was signiﬁcantly reduced in treated ani-
mals. At 1 week, GFAP was at the edge of detection, and in some experimental animals, completely eradicated.
We conclude that the administration of drugs can be controlled locally and non-invasively, opening the door
to many other known therapies, such as the cases that dexamethasone cannot be safely applied systemically in
large concentrations.
Published by Elsevier B.V.1. Introduction
The largest cell inundation into the acute spinal cord injury is an em-
igration of hematogenic macrophages, combined with the transforma-
tion of these phagocytes from resident microglia. After an initial cell
die-off caused directly by the primary central nervous system (CNS)
injury, an impressive glial accumulation occurs in the ﬁrst days of CNS
injury. This striking hyperplasia/hypertrophy of astrocytes at the lesion
forms the so-called astrocytic scar [1]. The classical view held that the
formation of the scar was a physical/chemical barrier to CNS nerve
regeneration and functional recovery in mammals [1–4]. However,
since the 1980s', trends in the understanding of astrocyte biochemistry
and their role as support cells for neurons both add to, and ameliorate,
this long-held view [5–10].
Themostwidely accepted tool for speciﬁc identiﬁcation of this exag-
gerated glial response is spiking local levels of glial ﬁbrillary acidic pro-
tein (GFAP) — a speciﬁc cellular product of reactive astrocytes [11,12].
GFAP is an intermediate ﬁlament transcribed by astrocytes in response
to cell insult. This marker has been used in investigations of astrocytic
gliosis in spinal cord injury (SCI), brain injury, neurodegenerativerch 408 S. University St. Westdisease [13,14], ischemic brain defects, and even brain tumors [15].
The objectives of this investigationwere twofold: 1. to test if a vertically
arranged “mat” of PpyNWs can serve as a reliable reservoir for drugs,
and reversibly deliver drugs to the bio-environment in response to a
distant applied electromagnetic ﬁeld (EMF); 2. to test if this released
drug can produce signiﬁcant biologic responses in live animal subjects.
To accomplish the latter, the well-known sensitivity of neuroinﬂamma-
tion (ie., reactive GFAP+ astrogliosis) to the glucocorticoid (DEX) was
employed. The release of DEX from PpyNWs placed on the spinal lesion
was instrumental in the virtual eradication of the speciﬁc GFAP marker
for astrogliosis — a signiﬁcant component of catastrophic spinal injury-
induced neuroinﬂammation [16]. This relationship was tested in a
GFAP-luc transgenic murine SCI model. Both objectives were met.
In this study, we performed a lower thoracic SCI using forceps com-
pression method in transgenic mice whichwere engineered to produce
a bioluminescent GFAP signals after an insult. The compression method
has been reported to activate astrocytes theﬁrst day after injury [17,18].
All control and experimental mice then underwent bioluminescent im-
aging to deﬁne speciﬁc locations and intensities of GFAP production or
its disappearance (for examples see [13,15,19]) with and without treat-
ment. The experimental treatment therapy was to insert a small patch
(~1–2 mm2) of a dense mat of vertically arranged PpyNWs (~200 nm
diameter × 1800 nm length) onto the injured spinal cord parenchyma.
This “patch” was manually placed into the open SCI lesion at the time
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anti-inﬂammation drugs.
2. Materials and methods
2.1. Preparation of the PpyNWs and Incorporation of the DEX Cargo
The nanofabrication and structure of DEX doped PpyNWs were re-
ported in Gao et al. [20]. Here we provide more methodological details
for this animal study. Brieﬂy, PpyNWs were fabricated on commercially
available anodisc inorganic templateswith a pore size of 200 nm. On the
one side of the templates, 100-nm thick gold was deposited by a Varian
E-beamevaporator to form a supportive and conductive base for further
procedures. 0.025Mdexamethasone 21-phosphate disodium salt (DEX,
Sigma), 0.2 M pyrrole (Py, Sigma), and 0.05 M NanoXact spherical gold
nanoparticles (AuNps, 10 nm diameter, NanoComposix, CA) were
mixed in the synthesis solution. The templates were immersed in the
solution and followed by electropolymerization, applying a constant po-
tential of 1 V using the electrochemical analyzer/workstation to form
the PpyNWs (Fig. 1A). During this polymerization, the gold nanoparti-
cles were physically embedded into polypyrrole nanowires during this
polymerization process (Fig. 1B). PpyNW ﬁlms were rinsed with Milli-
Q water for 5 min before and after AAO templates were removed by
3 M sodium hydroxide. It was then followed by 10% sulfuric acid treat-
ment and thoroughly rinsed with Milli-Q water. All PpyNW scaffolds
were prepared right before animal surgery, and stored in Milli-Q
water before implantation. Strict adherence to the use of sterile imple-
ments (autoclaved), fabrication environment (clean rooms), and sterile
solvents were consistently applied.
2.2. Electromagnetic ﬁeld stimulator
This integrated system is custom made within The Center for Paral-
ysis Research, Purdue University. A professional electronics schematic is
provided here for the knowledgeable reader and potential fabrication
specialist (Fig. 2). Its parts, construction, aswell as the development his-
tory and exact physical details of the alternating EMF have been provid-
ed in Gao et al. [20].
Importantly, the magnetic “coil”, which dispersed the EMF into the
environment, was rectangular in shape (approximately 3.0 × 3.8 cm)
consisting of 15 turns of copper wire. The highest intensity of the EMFFig. 1. A) Scanning electron and B) transmission electron micrographs of vertically arranged g
apex (arrows) due to the softness of the materials and preparation for SEM. (See also Gao et
gold nanoparticles imbedded in them, revealed as black particulate material. Scale bar A) 5 μmwas roughly the middle within this rectangle, which was positioned
over the arch of the animal's back — the lesion being oriented beneath
it approximate center (Fig. S1).
2.3. Surgical and treatment procedures
All aspects of animal care and treatment were carried out according
to guidelines of the Purdue Animal Care and Use Committee (PACUC),
and its approved protocol for this study. Female GFAP-luc transgenic
mice (Taconic Biosciences, Inc, NY) underwent surgery only when the
micewere 9–12weeks old and theirweightwas above 22g. Surgical an-
esthesia was induced by an intraperitoneal injection of ketamine
(90 mg/kg) and xylazine (10 mg/kg). Mice then underwent a bilateral,
hemilaminectomy procedure at the lower thoracic region. When the
dorsal surface of the spinal cord was exposed, it was compressed to ap-
proximately 1/2 of its depth using blunted forceps under stereoscopic il-
lumination (see Fig. S1).
For Ppy controls and the Ppy treatment group, the DEX-doped Ppy
ﬁlms were lifted on a single drop of sterile saline and deposited on the
dorsal domain of the injured spinal cord (see Fig. S1). The lesion was
surgically closed in layers, and the skin incision sutured. Animals were
then moved to their individual cages and warmed with incandescent
lights until recovery. All mice received buprenorphine HCl (0.1 cm3/
30 g body weight) after surgery and the next day to control post-surgi-
cal pain. In the active (experimental) treatment, the coil was brought
within a few mms of the surface of the suture-line of the injury site
with the animal quietedwith isoﬂurane gas sedation. The generator ex-
posed an approximately 25–40 G magnetic ﬁeld with 3000–5000 V/m
electrical ﬁeld at the injury sites to imbedded PpyNWs for 2 h daily.
When the isoﬂurane gas was removed, animals became awake and
alert almost immediately.
Micewere euthanized by beuthanasia (~0.22 ml/kg body weight) at
the end of experiment. Two animals were euthanized before 7 days due
to autophagy of their rear limbs, and they were replaced in the study
prior to the end of the experiment.
2.4. Whole animal bioluminescent imaging
At days 1, 3, and 7 after spinal cord injury, mice were imaged using a
Caliper IVIS Lumina II at theMulti-scale Imaging Center, Purdue Univer-
sity. The D-luciferin-K+ salt bioluminescent substrate (PerkinElmer)old embedded PpyNWs. These individual nanowires sometimes became attached at their
al. [20]). B). Individual nanowires are apparent in longitudinal section by TEM as are the
B) 2 μm.
Fig. 2. Electronic schematics of EMF stimulator system.
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peritoneal injection (IP) at 10 μl/g of bodyweight of the substrate before
imaging. All mice underwent imaging during a short period of
isoﬂurane anesthesia. Prior to the beginning of this experiment, a lucif-
erin kinetic studywas performed inmice to determine the time ofmax-
imum signal detection after IP introduction of the luciferin substrate.
This was determined to be between 15–25 min after the IP injection.
Quantitative collection of luminescent density data was conﬁned to
the regions of interest and analyzed within the range of 9.5e5 to
1.2e7 p/s/cm2/sr. Automated ROI measurement methods were used to
identify bioluminescent emissions automatically within a deﬁned
threshold. The total ﬂux of photons (or radiance) in each pixel
(photons/s) was integrated over the ROI area and then multiplied by
one steradian (sr). The upregulation of the GFAP after SCI can be visual-
ized as a pseudocolor signal (Fig. 3).Fig. 3. Bioluminescence images for GFAP signals in animal subjects. Untreated control, Ppy contr
Each column is one individual at 1 day, 3 days, and 7 days post injury (organized for each group
shownhere. The luminescent intensity given in units of radiance is shown at the scale bar at the
detection or completely absent. Note as well the clear GFAP signal from ear infections in all an2.5. Statistical analysis
All data are shown with standard error of the mean (±SEM). We
considered the data to be of normal distribution and used the student's
t test and ANOVA with Fisher's LSD post hoc to determine signiﬁcance.
The nature of the difference between the three means is shown in
Fig. 4. Signiﬁcance was determined by a P-value ≤ 0.05.
3. Results
3.1. Characteristics of Ppy mediated DEX drug delivery system
The deposition of gold nanoparticles in each individual PpyNW en-
hances the electrical conductivity of the forming polymer —making it
even more responsive to an externally applied electromagnetic ﬁeld.ol, and Ppy treatment (with EMF exposure) groups ofmice are illustrated from left to right.
). Each row is an individual animal and two individualmice for each of the three groups are
far right. Note that, typical of experimental animals, the GFAP signal is at the barest level of
imals at all times.
Fig. 4. The bar graph displays the quantitative data; GFAP radiance given as a function of
time post injury. Note that EMF-treated animals show striking and statistically signiﬁcant
reduced values compared to controls. * = P ≤ 0.05; ** = P ≤ 0.01.
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and has been reported heavily dependent on the application of an
electric current. It is believed that desired negative voltage potentials
passing through the Ppy polymer can repel the anionic drugs from the
Ppy and disrupt the electrostatic interaction between Ppy and doped
drugs. During the release process of Ppy, its structural conformation is
altered permitting the escape of “trapped” drugs or other molecules.
Since a voltage gradient/electric current is always present perpendicular
to the axis of a magnetic ﬁeld. The EMF is a means to produce a transi-
tory electrical ﬁeld within the body. This then does not require any
physical connection between a voltage source and the responding poly-
mer. The nature of an EMF penetrating tissues or bonesmakes our deliv-
ery strategies possible in many clinical applications. Full details of
waveform selection, the development of the PpyNWs, and quantitative
details of drug releasewere previously reported in Gao et al. [20]. In that
report we also show that a local concentration of 2.3mg/cm2 of DEX can
be delivered continuously for nearly 2 weeks. Only a fraction of this
capacity was required in this study.
3.2. Animal spinal cord injury model and its treatment
GFAP-luc transgenicmicewere chosen as the SCImodel because they
are genetically engineered to express luciferase by reactive astrocytes.
This permits multi-dimensional imaging of GFAP, and its changing dy-
namics, in the living animal. The spinal cord was gently compressed to
approximately 1/2 of its diameter using forceps during the experiment.
Our decision to lightly injure the cord was based on the desire to escape
signiﬁcant mortality in these transgenic animals for one week of obser-
vation, but to produce a measurable inﬂammation at the SCI site. Most
importantly, the activation of reactive astrogliosis after compression of
spinal cords can be observed the ﬁrst day after insult.
In this experiment, animals were classiﬁed to three groups:
• One SCI control group (control group) did not receive any implant.
• A second SCI control group (Ppy control group) possessed the nano-
wire patch placed onto the SCI in an identical manner to experimental
animals — but they were not exposed to an electromagnetic ﬁeld.
• The experimental mice, (Ppy treatment group) possessed the nano-
wire patch placed onto the SCI and localized EMF exposure was limit-
ed to one period of 2 h per day for oneweek at the local site of the SCI
(as illustrated in Fig. S1).
3.3. Astrogliosis reduction by PpyNWs remote drug releasing system
Bioluminescence images of typical untreated and sham-treated con-
trol animals, as well as experimental animals at days 1, 3 and 7 after SCIwere illustrated in Fig. 3. It is noteworthy that bioluminescent imaging
cannot provide raw data revealing; 1) the actual concentration of
GFAP or, 2) astrocyte cell density. It can reveal: 1) highly speciﬁc local-
ization of GFAP overexpression in the living animal, and 2) the relative
GFAP intensity between these animals via photon radiation of the
GFAP signature. This permits quantiﬁcation and statistical analysis of
bioluminescence data. These quantitative data by comparing relative
intensity (given in photons/s/cm2/sr) of the GFAP in the lesion were
described in Fig. 4.
There was a trend for the intensity of GFAP to slowly decay in all
Animals. This reduction was expected from the biology of reactive
astrocytes remaining localized to the SCI. However, a statistical differ-
ence between the GFAP signals during this decline in the two control
groups was not detected. Summarizing control applications, there
was: 1. always, and 2. in every control animal, 3. and at every time
point; a clear, unmistakable, and measurable GFAP signal.
In every experimental case, the EMF-induced release of DEX pro-
duced a very steep decline in the GFAP signature — especially apparent
by day 3. However, at the ﬁrst measurement day post-injury, GFAP ex-
pression in experimentally-treated mice was already 60% weaker than
control values. This difference did not reach signiﬁcance given the
wide variability of the means 24 h after surgical injury (P ≥ 0.05;
ANOVA with Fisher's LSD post hoc). By day 3, the reduction in the
GFAP signal in experimental animals compared to controlswas very sig-
niﬁcant — both visually and statistically. The standard error of the
means (SEM) of the experimental group compared to control samples
was strikingly reduced (P ≤ 0.01). At post-surgery day 7, 40% of EMF-
treated animals did not possess even a trace of the GFAP signal. The
other animals in this group revealed GFAP expression, but at the barest
level of detection. Figs. 3 and 4 provide both visual and quantitative
comparisons.
It is important to point out that GFAP positive ear infections in all
animals in this study provided a signiﬁcant, unanticipated, and telling
“internal control”. This ear infection was not reduced or otherwise af-
fected in either control or experimental mice. We suggest the reduction
of GFAP in spinal cord region is explained by the likelihood that concen-
trations of DEX released into the general circulation from the localized
nanosource which are virtually undetectable and of no signiﬁcance to
these remote (ear) infections. This observation provides formal proof
that the local release of DEX by smart nanowires in comparatively
high concentrations was restricted to the spinal cord lesion, where
DEX-doped PpyNWs were surgically placed and later exposed to a
directed EMF.
4. Discussion
The intermediate ﬁlament GFAP is an excellent indicator of particu-
larly ongoing CNS cellular inﬂammation. It is almost exclusively used as
amarker of astrogliosis in the damaged or diseased CNS, though it is not
exclusively a product of only astrocytes. For example, Schwann cell pro-
duction of GFAP in the peripheral nervous system (PNS) may represent
a marker for amyotrophic lateral sclerosis (Lou Gehrig's disease; [14]).
The molecular mechanisms supporting the shift to GFAP expression
via controlling its promoter gene is an expanding area of research. The
glucocorticoid DEX is a well-understood and powerful inhibitor of
inﬂammation in general — and of GFAP production in particular. For
example, DEX coated metallic and silicon probes and implants do not
induce signiﬁcant astrogliosis in brain, and increase survival of
neurons compared to uncoated comparators. This suggests that surface
coated DEX might be very beneﬁcial during medical application of
neuroprosthetics [16,21,22].We exploited this drug/cellular target rela-
tionship to test the delivery of DEX via “smart” nanowires. Furthermore,
we chose the SCI since the region of gliosis is restricted to a
predetermined region of spinal cord damage — encased as it is within
the bony vertebral column. Finally, the dynamics of reactive gliosis
and GFAP production after SCI are well described in the literature.
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has been commonly used in many tissue engineering studies, especially
for neural interfaces and regeneration [23,24]. Ppy is not biodegradable
though a biodegradable co-polymer form has been reported [25]. These
biodegradable polymers, such as poly(L-lactide) or poly(ε-caprolactone),
are not conductive. Thus, the process of fabricating this biodegradable
polypyrrole could render it less sensitive to DC current (and thus
EMFs). However, we think that a biodegradable conductive polymer ar-
chitecture that is responsive to externally applied EMFs is a future direc-
tion for our research. The PpyNW nanoarchitecture itself does not
represent a marked addition to the amalgam of tissues and cells where
it is placed. Through scaffold synthesis produces a polymer matrix con-
taining gold nanoparticles— the latter are not generally exposed to sur-
rounding biological tissues and ﬂuids. Moreover, since polypyrrole is not
biodegradable, there is very low probability of gold nanoparticle distri-
bution from its polymer source. Also, gold nanoparticles based clinical
applications have been widely developed for chemical sensing,
photothermal therapies, imaging, and drug delivery. For example,
many gold thiolates based commercial products are available for treating
rheumatoid arthritis. Traditionally, gold nanoparticles above 5 nm diam-
eter were considered as “safe” and “chemically inert” bulk gold [26].
Thus, the biological “imprint” of PpyNWs placed into a region of interest
within the body is insigniﬁcant.
This laboratory in particular, has historically been concerned with
the safety of EMF exposure to the human body during the developing
of EMF associated medical application [27]. Although some clinical or
pre-clinical application of EMFs (particularly in diathermy, hyperther-
mia, and ablation for cancer treatment) has shown the beneﬁts of
electromagnetic-based clinical devices [28], localized thermoregula-
tions failurewould bemajor adverse effects with the introduction of ra-
diofrequency energy into a biological system, and its potential outcomes
varying with exposure durations, frequencies, and tissue conditions.
The available data did not reveal any evidence of DNA damage, carcino-
gen factors, or immune system dysfunction according to the review
reports fromMeltz, M.L. and Black, D. R. [29,30] but negative and incon-
clusive results were also presented in many literatures. Thus, a closer
look of EMF effects in toxicity needs to be further examined.
In this study, we show the controlled release concomitant with
building concentration of drug cargo from such a nanosource is not in-
signiﬁcant. The peculiar architecture of these nanowires, with their ex-
tended surface area, has been measured to steadily release DEX for 16
continuous days during in vitro experimentation [20]. The in vivo test
here used only a fraction of the available DEX reservoir of the PpyNWs.
Moreover, the remote control of such delivery is by a simple and reliable
application. The EMF required to induce drug delivery is completely
non-invasive to the body, and of a character to be controllable.
The biologically compatible PpyNW-based drug delivery system uti-
lizes physical placement to target a localized site, and is not encumbered
by side effects and other unknowns associated with systemic delivery
including cell-based recognition regimens by immunologically
targeting. The PpyNWs are simply placed where they are to be most ef-
fective. This can be as simple as the placement used here, or alternately,
implantation/insertion via a biopsy needle. This scheme is likely to be
indicated in many emerging and expected clinical pathological applica-
tions. Thiswould include the resolution of early tumor formations in the
breast, lung, prostrate, etc., where clinical imaging indeed reveals early
circumscribed and localized neoplasms. It is also called for in the treat-
ment of localized CNS injury — including local regions of ischemia in
stroke, as well as many localized, resistant, and unresponsive infections
and ulcerations in critical organs and tissues. The method of nanowire
preparation used here is available for many other therapeutic drugs,
such as chemotoxin and growth factors, as these agents can be initially
synthesized with polypyrrole during polymerization. The therapeutic
agent of choice could be chosen based on the clinical problem to be ad-
dressed and could be released with desired local concentrations unat-
tainable by other means of delivery.Therefore, as shown here, the tissue level response to the clinically
relevant compoundswhich can be released for days toweeks into a cho-
sen local environment can have both dramatic and sustained outcomes
depending on the treatment.
5. Conclusions
This novel polypyrrole-based delivery system can deliver drugs
continuously for many days to speciﬁc localized tissue — reversibly
controlled by external EMF stimulation. Using transgenic mice; a
typical, acute, reactive astrogliosis accompanying a lower thoracic
spinal cord injury was reduced or eliminated by the Ppy-mediated
delivery of DEX in only treated-animals. This dramatic reduction was
determined using an astrocyte speciﬁc glial marker, GFAP, expressed
endogenously in spinal cord injured transgenic GFAP-luc mice by
whole-animal bioluminescence evaluation. These data have proven
that a continuous localized corticosteroid drug release can indeed
ameliorate inﬂammatory reactive gliosis induced by spinal cord trauma.
Furthermore, to our knowledge, this is the ﬁrst demonstration of a
successful controlled release of a powerful anti-inﬂammatory drug by
EMF-sensitive conductive polymers in an experimental clinical animal
model.
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